Reboxetine Combination in Treatment-resistant Depression
to Selective Serotonin Reuptake Inhibitors
by
Lopez-Munoz F, Alamo C, Rubio G, Garcia-Garcia P, Pardo A.
1Pharmacology Department, Faculty of Medicine,
University of Alcala, Madrid, Spain.
Pharmacopsychiatry. 2007 Jan;40(1):14-9.

ABSTRACT

INTRODUCTION: Treatment-resistant depression is a relatively common clinical occurrence: between 60-70% of depressive patients fail to achieve total remission to the initial treatment with selective serotonin reuptake inhibitors (SSRI). METHODS: In this prospective 12-week open-label study, we evaluated the effectiveness of the addition of reboxetine to 141 outpatients diagnosed with major depressive disorder, according to DSM-IV-TR criteria, who were partial responders or non-responders over a period of 6 weeks, to previous treatment in monotherapy with SSRI. Evaluation of antidepressant efficacy was carried out through the application of the Hamilton Depression Rating Scale (HDRS) and the Clinical Global Impressions-Global Improvement Scale (CGI-I). Data were analyzed on an intent-to-treat basis, using the last-observation-carried-forward method. RESULTS: Mean score on the HDRS at baseline was 26.24+/-7.21, falling to 13.96+/-8.00 in week 12 (mean decrease of 46.79%; p<0.0001) The percentages of responders (HDRS total score >/=50%) and patients considered as benefiting from complete remission (HDRS score

Efficacy
Selectivity
Reboxetine
Venlafaxine
NARIs and SSRIs
Sexual side-effects
Noradrenaline and mood
Catecholamine depletion
Selectivity or multiplicity?
Reboxetine and the elderly
Noradrenaline reuptake inhibition
Sexual function: paroxeine v reboxetine

Refs
and further reading

HOME
HedWeb
Nootropics
cocaine.wiki
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family